Allergy Therapy and Allergy Immunotherapy in Childhood

被引:4
|
作者
Klimek, Ludger [1 ,2 ,3 ,4 ,5 ,6 ]
Chaker, Adam M. [7 ,8 ]
Casper, Ingrid [9 ]
Sperl, Annette [9 ,10 ]
Strieth, Sebastian [11 ,12 ]
Moesges, Ralph [13 ,14 ,15 ,16 ,17 ]
机构
[1] Zentrums Rhinol & Allergol Wiesbaden, Quellen 10, D-65183 Wiesbaden, Germany
[2] ADA, Dreieich, Germany
[3] Deutsch AllergieLiga, Kronberg, Germany
[4] EAACI, ENT Sect, Zurich, Switzerland
[5] ExCom EAACI, Zurich, Switzerland
[6] Deutsch Akad Allergol & Umweltmed, Dreieich, Germany
[7] Tech Univ Munich, TUM Med Sch, Klinikum Rechts Isar, HNO Klin, Munich, Germany
[8] Tech Univ Munich, TUM Med Sch, Klinikum Rechts Isar, Zentrum Allergie & Umwelt, Munich, Germany
[9] Zentrum Rhinol & Allergol, Wiesbaden, Germany
[10] LMU Munchen, HNO Klin, Munich, Germany
[11] Goethe Univ, HNO Klin, Frankfurt, Germany
[12] Univ HNO Klin Mainz, Mainz, Germany
[13] Allergol & Med Informat Koln, Hals Nasen Ohrenheilkunde, Cologne, Germany
[14] Univ Klinikum Koln, Inst Med Stat Informat & Epidemiol, Cologne, Germany
[15] Univ Cologne, Ethikkommiss, Cologne, Germany
[16] EAACI, Exekutiv Komitees, Zurich, Switzerland
[17] GAA, INTERASMA, Berlin, Germany
关键词
HOUSE-DUST MITE; GRASS-POLLEN IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; FOLLOW-UP; LONG-TERM; CHILDREN; ASTHMA; PREVENTION; SENSITIZATIONS; ATOPY;
D O I
10.1055/a-0899-1202
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Adequate diagnostical workup for respiratory allergies and consequent therapy in children determine the individual course of disease. Therapy consists first of symptomatic treatment and includes in the next step the important option of allergy immunotherapy (AIT) as a causative treatment of disease. Children are an important target group for AIT, since AIT offers a proven longterm effect including secondary preventive properties with not only transiently reduced symptoms but moreover longstanding and beneficial disease modification. New strategies with AIT as primary and secondary preventive interventions are being evaluated with the aim to reduce clinical appearance and the amount and extent of sensitizations to allergens in high-risk children. Until implementation of such potentially preventive strategies the currently more attractive early intervention is the early adoption of AIT within the first 12 to 24 months of onset of symptoms as a first-line treatment of allergic rhinitis. Simplified treatment protocols can improve the willingness to perform an AIT and the adherence and compliance of children and their parents. The overall goal is to make AIT as the most important treatment modality available to more affected children. © 2020 Inderscience Enterprises Ltd.. All rights reserved.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 50 条
  • [1] Allergen immunotherapy for prevention and treatment of respiratory allergy in childhood
    Saranz, Ricardo J.
    Lozano, Alejandro
    Caceres, Maria E.
    Arnolt, Roque G.
    Maspero, Jorge F.
    Bozzola, Cesar M.
    Neffen, Hugo E.
    Croce, Victor H.
    Gualtieri, Octavio
    Procopio, Norberto
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2010, 108 (03): : 258 - 265
  • [2] Immunotherapy in allergy
    Sapan, Nihat
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2010, 45 (03): : 225 - 231
  • [3] EAACI guidelines on allergen immunotherapy: Prevention of allergy
    Halken, Susanne
    Larenas-Linnemann, Desiree
    Roberts, Graham
    Calderon, Moises A.
    Angier, Elisabeth
    Pfaar, Oliver
    Ryan, Dermot
    Agache, Ioana
    Ansotegui, Ignacio J.
    Arasi, Stefania
    Du Toit, George
    Fernandez-Rivas, Montserrat
    van Wijk, Roy Geerth
    Jutel, Marek
    Kleine-Tebbe, Joerg
    Lau, Susanne
    Matricardi, Paolo M.
    Pajno, Giovanni B.
    Papadopoulos, Nikolaos G.
    Penagos, Martin
    Santos, Alexandra F.
    Sturm, Gunter J.
    Timmermans, Frans
    van Ree, R.
    Varga, Eva-Maria
    Wahn, Ulrich
    Kristiansen, Maria
    Dhami, Sangeeta
    Sheikh, Aziz
    Muraro, Antonella
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2017, 28 (08) : 728 - 745
  • [4] Is immunotherapy justified in the treatment of respiratory allergy?
    Munoz-Lopez, F.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2007, 35 (03) : 79 - 82
  • [5] Allergen Immunotherapy in Pediatric Respiratory Allergy
    Doroudchi, Ali
    Imam, Kamran
    Lloret, Maria Ines Garcia
    CURRENT TREATMENT OPTIONS IN ALLERGY, 2021, 8 (02) : 147 - 160
  • [6] Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis
    Hankin, Cheryl S.
    Cox, Linda
    Bronstone, Amy
    Wang, Zhaohui
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (04) : 1084 - 1091
  • [7] Plain Language Summary: Immunotherapy for Inhalant Allergy
    Gurgel, Richard K.
    Baroody, Fuad M.
    Damask, Cecelia C.
    Mims, James Whit
    Gardner, Donna D.
    Reger, Christine M.
    Reyes, Joe
    Dhepyasuwan, Nui
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 170 (03) : 668 - 674
  • [8] House dust allergy and immunotherapy
    Thomas, Wayne R.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (10) : 1469 - 1478
  • [9] Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis
    Kristiansen, Maria
    Dhami, Sangeeta
    Netuveli, Gopal
    Halken, Susanne
    Muraro, Antonella
    Roberts, Graham
    Larenas-Linnemann, Desiree
    Calderon, Moises A.
    Penagos, Martin
    Du Toit, George
    Ansotegui, Ignacio J.
    Kleine-Tebbe, Joerg
    Lau, Susanne
    Matricardi, Paolo Maria
    Pajno, Giovanni
    Papadopoulos, Nikolaos G.
    Pfaar, Oliver
    Ryan, Dermot
    Santos, Alexandra F.
    Timmermanns, Frans
    Wahn, Ulrich
    Sheikh, Aziz
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2017, 28 (01) : 18 - 29
  • [10] What is the future for specific immunotherapy in pollinic allergy treatment?
    Didier, A.
    REVUE DES MALADIES RESPIRATOIRES, 2009, 26 (06) : 693 - 697